iX Biopharma has high hopes for drug spin-off
After the planned HK listing of its pharmaceutical and medical cannabis business, the company will focus on nutraceuticals. BY JANICE HENG
Add BT as a preferred source
CATALIST-LISTED iX Biopharma wishes investors would focus less on its current topline or bottom-line, and more on the potential of its products and patented technology.
This search for understanding investors is one reason it is looking to spin off its pharmaceutical and medicinal cannabis business for a listing in Hong Kong, said director of corporate affairs Yee Chia Hsing.
"The type of conversation that they have (in Hong Kong) is very different. They don't ask you about when you turn profitable ... They talk about your drug pipeline, they try to understand the size of the market."
TRENDING NOW
CSE Global independent director quits after clashes with chairman Eugene Lai over board refresh
What’s wrong with Orchard Road? Experts weigh in on the street’s cachet and its future
‘I felt like dying’: Thai Singha beer scion speaks up after disclosure of alleged sexual abuse
Rare brutalist Singapore house opens to the public before changing hands
